361P Tucatinib plus trastuzumab in patients (Pts) with HER2-positive metastatic colorectal cancer (mCRC): Patient-reported outcomes (PROs) from ph II study MOUNTAINEER.

Authors :: Wu, C.
Strickler, J.H.
Cercek, A.
Siena, S.
André, T.
Ng, K.
Van Cutsem, E.
Paulson, A.S.
Hubbard, J.
Coveler, A.
Fountzilas, C.
Kardosh, A.
Kasi, P.M.
Lenz, H.J.
Ciombor, K.K.
Elez Fernandez, M.E.
Hsu, L-I.
Stecher, M.
Zhao, K.
Bekaii-Saab, T.
Source :: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS700-S701. 2p.
Publication Year :: 2022

Subjects :: *PATIENT reported outcome measures
*COLORECTAL cancer
*METASTASIS
*TRASTUZUMAB
*MOUNTAINEERING

Full Text Access

Tools